Synthesis and application of heptamethine cyanine compound capable of stimulating response to release hydrogen sulfide

By releasing stimulus-responsive supramolecular diagnosis and treatment integrated reagents of H2S gas in tumor tissues, the skin burns and tumor recurrence problems of traditional photothermal therapy are solved, and the treatment selectivity and safety of high and low temperatures are achieved. It provides efficient tumor diagnosis and treatment effects.

CN118978516AActive Publication Date: 2024-11-19QINGDAO UNIV OF SCI & TECH

Patent Information

Application Number
CN202411056719.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-19
Estimated Expiration
2044-08-02

AI Technical Summary

Technical Problem

Traditional photothermal therapy causes skin burns and inflammation at high temperatures, and low-temperature photothermal therapy is difficult to kill cancer cells deep and around blood vessels, leading to tumor recurrence, and single photothermal therapy lacks targeted and safe.

Method used

Develop a stimulus-responsive supramolecular diagnosis and treatment integrated reagent based on stimulus-responsive supramolecular diagnosis and treatment, targeting tumor tissues through the EPR effect, combining H2S donor to release stimulus-responsive and H2S gas at specific excitation wavelengths, achieving low background fluorescence at tumor sites Imaging and precision photothermal/photodynamic therapy have the option of high and low temperature treatment.

Benefits of technology

It has achieved efficient diagnosis and treatment integration of tumor sites, reduced damage to normal tissues, reduced inflammatory response caused by high temperatures, and provided an optional treatment mode of high temperature/low temperature, with excellent biosafety and commercialization potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention provides synthesis and application of a heptamethine cyanine compound capable of stimulating response to release of hydrogen sulfide, and provides a micro-nano structure formed by self-assembly of a structure shown in a formula (I) or an isomer, a pharmaceutically acceptable salt, a hydrate or a solvate of the structure in a water solution, the invention also relates to preparation of the pharmaceutical composition and application of the pharmaceutical composition in preparation of fluorescent probes, H2S donors and phototherapy drugs, preparation of drugs for diagnosis and / or treatment of cancers, and phototherapy combined gas therapy and stimuli-responsive release drugs. The compound provided by the invention can be accumulated at a tumor part, can realize aggregation structure conversion and H2S gas release by responding to unique oxidation-reduction stimulation of a tumor microenvironment, and can be used for preparing an H2S gas-containing compound under the irradiation of a specific excitation wavelength. Accurate phototherapy combined with gas therapy on the tumor in an aggregation state and low-background long-acting fluorescence imaging at the tumor after aggregation and disintegration are realized. The system has two tumor treatment modes, is good in tumor treatment effect, small in wound, high in fluorescence imaging precision and long in time, has excellent biological safety and realizes integration of diagnosis and treatment of tumor parts.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of chemical pharmacy, and relates to the synthesis and application of a heptamethine cyanine compound that releases hydrogen sulfide in response to stimulation. Hydrogen sulfide gas and heptamethine cyanine molecules can be released under the stimulation of the external environment, so that the compound has the effects of both gas therapy and photothermal therapy, and can achieve both high temperature and low temperature treatment modes for tumors. Background Art

[0002] As a disease that seriously threatens human life, early diagnosis and treatment of cancer are crucial. Photothermal therapy (PTT) is one of the most effective cancer treatment strategies known, but the high temperature of traditional photothermal therapy will inevitably burn the skin, leading to long-term inflammation, permanent tissue damage and tumor regeneration. Low-temperature PTT below 45°C has been shown to reduce the risk of normal tissue damage, but due to the limited penetration of the therapeutic laser and the rapid heat dissipation by blood flow, cancer cells located deep inside and around blood vessels are almost impossible to be killed, and thus continue to proliferate, leading to tumor recurrence. Therefore, it is very important to seek other therapies in combination with photothermal therapy to achieve a safe and powerful tumor inhibition effect.

[0003] In recent years, gas therapy (GT) has attracted much attention due to its high efficiency and lack of side effects. Hydrogen sulfide (H2S) is an endogenous biogas transmitter with cytoprotective effects. At high concentrations, it can disrupt mitochondrial homeostasis and interfere with the respiratory chain by reducing the activation of cytochrome c oxidase (COX IV), thereby inhibiting the synthesis of ATP and downregulating the level of energy-dependent heat shock protein 70 (HSP70). This will be an effective and robust strategy to reverse HSP70-mediated thermal tolerance. H2S can inhibit the NF-κB pathway and downregulate inducible nitric oxide synthase (iNOS) through sulfide, thereby inhibiting inflammatory stimuli, which lays a solid theoretical foundation for H2S to downregulate inflammation caused by high temperature in photothermal therapy.

[0004] COS / H2S donors are usually constructed based on the self-elimination reaction of 4-aminobenzyl alcohol. This linker molecule is often used to connect specific substrates to target molecules through stable chemical bonds. The substrate is removed by external stimulation to form aniline derivatives, which undergo a rapid self-elimination reaction through 1,6-elimination to form azaquinone, which then undergoes a decarboxylation process to degrade and release carbonyl sulfide (COS), which is then rapidly converted into H2S through the ubiquitous carbonic anhydrase (CA). Summary of the invention

[0005] The purpose of the present invention is to solve the above-mentioned problems existing in the prior art, and propose a supramolecular diagnosis and treatment integrated reagent based on heptamethine chuanjing and its application, which connects heptamethine chuanjing molecules and H2S donors through stimulus-responsive linkers, overcomes the shortcomings of single phototherapy, and provides new ideas for tumor treatment. At the same time, the nanoparticles can be targeted and enriched in tumor tissues through the EPR effect, induce responses under tumor-specific microenvironments, release heptamethine chuanjing small molecules and H2S gas, and under the irradiation of specific excitation wavelengths, can achieve low-background long-term fluorescence imaging of the tumor site while achieving precise photothermal / photodynamic therapy effects on the tumor, realizing integrated diagnosis and treatment of the tumor site, and at the same time, H2S gas can inhibit the expression of heat shock protein 70 by inhibiting mitochondrial respiration, so as to achieve low-temperature treatment of tumors and reduce damage to normal tissues. It is exciting that under the conditions of traditional high-temperature photothermal therapy, H2S gas can reduce the overactive inflammatory response caused by high temperature, and realize a treatment mode in which high temperature / low temperature can be selected on demand.

[0006] The technical solution of the present invention is:

[0007] A diagnostic and therapeutic integrated compound with stimulus responsiveness, wherein the compound has a micro-nano structure formed by self-assembly in an aqueous solution of a structure represented by formula (I) or an isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof:

[0008]

[0009] In the above formula (I): W is a stimulus response group, including

[0010] In the formula (I), X, Y and Z are independently selected from O or S.

[0011] Furthermore, the compounds are compounds Ⅰ-1, Ⅰ-2, Ⅰ-3, Ⅰ-4, Ⅰ-5, Ⅰ-6, Ⅰ-7, Ⅰ-8, Ⅰ-9, Ⅰ-10, Ⅰ-11, Ⅰ-12, and Ⅰ-13.

[0012] Furthermore, the micro-nano structure described in the present invention is a nano-microsphere structure formed by self-assembly of a compound having a structure represented by formula (I), its isomer, pharmaceutically acceptable salt, hydrate or solvate in an aqueous solution.

[0013] Preferably, the micro-nano structure of Compound I is formed by self-assembly of Compound I (including Compound I-1 to Compound I-13 in Table 1) in an aqueous solution.

[0014] The final preferred value is 30nm to 200nm.

[0015] The present invention also provides a method for preparing the micro-nano structure, comprising the following steps:

[0016] 1) dissolving a compound having a structure represented by formula (I), an isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof in an organic solvent;

[0017] The organic solvent is a mixture of one or more of alkanes, olefins, aromatic hydrocarbons, alcohols, ketones, aldehydes, carboxylic acids, esters or ethers; specifically, the organic solvent is a mixture of one or more of dimethyl sulfoxide, N,N-dimethylformamide, methanol, ethanol, ethylene glycol, n-propanol, isopropanol, propylene glycol, glycerol, n-butanol, isobutanol, butanediol or polyethylene glycol, acetone, dichloromethane or acetonitrile; preferably dimethyl sulfoxide.

[0018] 2) adding the dissolved solution into water to obtain a compound solution with a final concentration of 1 nM to 1 M;

[0019] The final concentration is preferably 10 nM to 1 mM.

[0020] 3) The compounds self-assemble in aqueous solution to form micro-nanostructures.

[0021] The preparation method is simple, convenient and suitable for large-scale production.

[0022] The present invention also provides a composition comprising:

[0023] 1) A therapeutically effective dose of a compound having a structure represented by formula (I) or its isomer, pharmaceutically acceptable salt, hydrate or solvate

[0024] 2) Pharmaceutically acceptable carrier.

[0025] Preferably, the pharmaceutically acceptable carrier comprises a diluent, a disintegrant, an excipient, a binder, a stabilizer or a combination thereof.

[0026] The invention relates to the use of the compound provided by the invention in preparing medicines for treating cancer and various tissue inflammations.

[0027] The cancer includes esophageal cancer, non-small cell lung cancer, biliary tract cancer, head and neck cancer, Barrett's esophagitis, bladder cancer, colorectal cancer, pancreatic cancer, ovarian cancer, prostate cancer, brain tumor, breast cancer or skin cancer, and the skin cancer includes melanoma. The tissue inflammation includes myocarditis, tracheitis, bronchitis, pharyngitis, tonsillitis, enteritis, gastritis, and duodenitis.

[0028] The present invention provides the use of the micro-nano structure in preparing a phototherapy combined with gas therapy drug. Preferably, the phototherapy drug is a photothermal therapy drug, a photodynamic therapy drug or a photoacoustic therapy drug; and the H2S donor is a COS / H2S donor.

[0029] The present invention also provides the use of micro-nano structures in preparing stimulus-responsive release drugs. The stimulus-responsive release includes active oxygen response, reduction response, enzyme response, pH response, hypoxia response, temperature response, light response, acoustic response and magnetic response.

[0030] The present invention also provides a method for performing phototherapy on a target area of ​​a subject, comprising:

[0031] 1) Providing the micro-nano structure;

[0032] 2) administering the micro-nanostructure to a subject;

[0033] 3) waiting for the micro-nanostructure to be enriched in the target area;

[0034] 3) Using light in the excitation wavelength band of the micro-nanostructure to irradiate the target area of ​​the subject, preferably, using 808 nm light waves for irradiation.

[0035] Beneficial effects of the present invention:

[0036] (1) The compounds provided by the present invention can self-assemble into micro-nano structures in aqueous solution. Through the EPR effect, the nanoparticles can be circulated through the blood, stably and efficiently targeting tumor tissues, and stimulated to respond under the unique redox microenvironment of the tumor site, thereby accurately releasing H2S gas and heptamethine cyanine molecules. Under near-infrared light irradiation, low-background enhanced fluorescence imaging of the tumor site can be achieved, and the compounds can be used for cancer photothermal / gas combined treatment under the guidance of near-infrared fluorescence imaging, showing higher biosafety, excellent fluorescence imaging accuracy and photothermal / gas combined treatment effect, and have broad prospects in cancer diagnosis and treatment.

[0037] (2) The formed micro-nanostructure has high dimensional stability, high biosafety, excellent photostability and excellent tumor targeting, and can achieve stimulus-responsive breaking of connecting bonds and release of H2S gas under the unique pathological microenvironment of the tumor. It has good targeting and imaging effects and can achieve high temperature or low temperature treatment modes. It has great market value and broad commercial prospects.

[0038] (3) The present invention also provides the use of the compound represented by formula (I) for preparing phototherapy combined with gas therapy drugs, and drugs for diagnosing and treating cancer. The drug has good therapeutic effects and little trauma, and has great potential in commercialization and clinical application. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 The synthetic route of compound Ⅰ-1 provided by the present invention;

[0040] Figure 2is the UV absorption spectrum of compound Ⅰ-1 in different polar solvents;

[0041] Figure 3 is the fluorescence emission spectra of compound Ⅰ-1 in different polar solvents;

[0042] Figure 4 It is a transmission electron microscopy image of nanospheres formed by self-assembly of compound Ⅰ-1 in aqueous solution;

[0043] Figure 5 The particle size test results of the compound Ⅰ-1 provided by the present invention in aqueous solution;

[0044] Figure 6 The cyclic temperature change diagram of compound Ⅰ-1 and control group under 808nm laser irradiation;

[0045] Figure 7 The temperature change diagram of compound Ⅰ-1 with different concentrations under 808nm laser irradiation;

[0046] Figure 8 The graph is a graph showing the change in ultraviolet absorption of the active oxygen scavenger DPBF when an aqueous solution containing compound Ⅰ-1 is irradiated with 808nm laser;

[0047] Fig. 9 This is the cell co-localization image after compound Ⅰ-1 is engulfed by tumor cells;

[0048] Fig.10 The reactive oxygen species produced in 4T1 cells after compound Ⅰ-1 was treated in different ways;

[0049] Fig.11 The dark toxicity and phototoxicity of compound Ⅰ-1 to 4T1 cells;

[0050] Fig.12 Live-dead fluorescence imaging of compound Ⅰ-1 on 4T1 cells;

[0051] Fig.13 The production of H2S by compound I-1 in 4T1 cells;

[0052] Fig.14 The fluorescence imaging images of the tumor site at different time points after compound Ⅰ-1 was intravenously injected into mice;

[0053] Fig.15 Photoacoustic imaging of mice at different time points after compound Ⅰ-1 was injected into the tail vein of mice;

[0054] Fig.16 This is the thermal imaging image of compound Ⅰ-1 in vivo treatment of mice;

[0055] Fig.17 This is the in vivo treatment image of compound Ⅰ-1 in mice;

[0056] Fig.18 The images of tumor volume changes after intravenous injection of compound Ⅰ-1 in tumor-bearing mice and treatment;

[0057] Fig.19 The image of weight change of tumor-bearing mice after intravenous injection of compound Ⅰ-1 and treatment;

[0058] Fig. 20 Liver function and blood routine test results after intravenous injection of compound Ⅰ-1 in mice;

[0059] Fig.21 H&E staining images of heart, liver, spleen, lung and kidney sections of tumor-bearing mice after intravenous injection of compound Ⅰ-1 and treatment; DETAILED DESCRIPTION

[0060] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0061] In order to further understand the present invention, the present invention will be further described in conjunction with the accompanying drawings and embodiments.

[0062] The present invention provides some specific examples of compounds, including compounds I-1 to I-13 shown in the following Table 1:

[0063] Table 1 Structural formula of compounds Ⅰ-1 to Ⅰ-13

[0064]

[0065]

[0066] The above compounds can be synthesized by the following reaction formula:

[0067]

[0068] The main synthesis steps include:

[0069] (1) providing compounds A, B, C, D and E respectively;

[0070]

[0071] Synthesis of compound A:

[0072] Compound 1' and Compound 2' were dissolved in anhydrous ethanol and refluxed with stirring for 12 hours. After the reaction was completed, the purple-red precipitate was filtered and dried under vacuum to obtain Compound A without purification.

[0073] Synthesis of compound B:

[0074]

[0075] 3' and 4' were added to acetonitrile and heated to 110°C for 24 hours under reflux. The solvent was evaporated under vacuum and the obtained solid was washed with ether three times to obtain a pink solid.

[0076] Compounds D, E and F were purchased directly.

[0077] (2) Compound C and Compound D were dissolved in dichloromethane, EDC·HCl and DMAP were added, and the mixture was reacted at room temperature overnight. Compound E was added to continue the reaction, and the mixture was washed three times with saturated aqueous ammonium chloride solution and saturated aqueous sodium chloride solution. After removing water, the obtained solid was purified by column chromatography. The product and Compound F were dissolved in dichloromethane, pyridine was added, and the mixture was reacted at room temperature overnight. The solid was washed three times with water and purified by column chromatography to obtain the product Compound I.

[0078] Example 1 Synthesis of Compound Ⅰ-1 and its Fluorescence Properties

[0079] like Figure 1 As shown, the synthesis of compound Ⅰ-1 includes the following steps:

[0080] 1) Synthesis of compound 1': 1.46 g of malononitrile and 0.93 g of magnesium ethoxide were added to 15 mL of ethanol, and then 0.75 mL of 3-hydroxy-3-methylbutane-2-one was added, and the mixture was heated to 60° C. and reacted for 12 hours. The solvent was removed by vacuum rotary evaporation, and the obtained solid was purified by column chromatography to obtain the target product 1. 1 H NMR (400MHz, CDCl3): δ (ppm): 2.36 (s, 3H), 1.63 (s, 6H).

[0081] 2) Synthesis of compound 2': 30 mL of DCM and 30 mL of DMF were added to a reaction bottle under an ice bath and stirred, 26.3 mL of POCl3 was added under constant pressure and stirred, and then 7.95 mL of cyclohexanone was added and heated to 80°C for 3 hours. After the reaction, the product was poured into crushed ice to quench the reaction, and then placed in a refrigerator overnight, and the solvent was removed by vacuum rotary evaporation to obtain a crude product, compound 2', which was directly carried out to the next step of synthesis reaction.

[0082] 3) Synthesis of compound 6: 0.5 g of 5-chloro-2,3,3-trimethylindole and 2.01 g of iodoethanol were added to 50 mL of acetonitrile. The mixture was refluxed at 110°C for 24 hours. After cooling to room temperature, the mixture was recrystallized with ether and filtered to obtain a crude product 6, which was used directly in the next step without purification.

[0083] 4) Synthesis of compound A: as described above.

[0084] 5) Synthesis of Compound 7: 0.4 g of Compound A, 0.44 g of Compound 6 and a few drops of pyridine were dissolved in 5 mL of ethanol, heated to 90° C., refluxed for 6 hours, and column chromatography was used to obtain Compound 7.

[0085] 6) Synthesis of compound 9: 300 mg of compound 7 and 50 mg of compound 8 were dissolved in a solvent of dichloromethane (3 mL), and 0.28 g of EDC·HCl and 0.05 g of DMAP were added dropwise under an ice bath. The mixture was reacted at room temperature overnight, and then 40 mL of dichloromethane was added. The mixture was washed three times with 50 mL of saturated NH4Cl aqueous solution and saturated brine, respectively. After dehydration with anhydrous Na2SO4, the solvent was evaporated under vacuum, and the obtained solid was purified by column chromatography to obtain the target compound 9.

[0086] 7) Synthesis of compound 11: 368.25 mg of compound 9 and 68 mg of compound 10 were dissolved in 5 mL of dichloromethane, and 0.28 g of EDC·HCl and 0.05 g of DMAP were added dropwise under ice bath. The mixture was reacted at room temperature overnight, and then 40 mL of dichloromethane was added. The mixture was washed three times with 50 mL of saturated NH4Cl aqueous solution and saturated brine, respectively. After dehydration with anhydrous Na2SO4, the solvent was evaporated under vacuum, and the obtained solid was purified by column chromatography to obtain the target compound 11.

[0087] 1 H NMR (400MHz, DMSO-d6): δ8.39(d,J=14.5Hz,1H), 8.11(d,J=13.8Hz,1H), 7.54(d,J=7.4Hz,1H), 7.42–7.31(m,4H),7.19(t,J=7.2Hz,1H),7.09–7.02(m,2H),6.24(dd,J=25.1,14.2Hz,2H),4.49 (s,2H),4.44(s,4H),2.68(dt,J=26.9,7.2Hz,9H),2.55(d,J=7.0Hz,2H),2.24(t,J=7.4Hz,2H), 1.95(p,J=7.2Hz,2H), 1.83(p,J=7.5,6.8Hz,2H), 1.69(p,J=7.3Hz,3H), 1.63(d,J=3.9Hz,12H).

[0088] 8) Synthesis of compound Ⅰ-1: 120 mg of compound 11 and 50 mg of compound 12 were dissolved in 3 mL of dichloromethane in an ice bath. After stirring at 0°C for half an hour, 50 μL of pyridine was added and the mixture was returned to room temperature for 12 hours. The mixture was washed three times with 20 mL of saturated brine and water respectively. After dehydration with anhydrous Na2SO4, the solvent was evaporated under vacuum and the obtained solid was purified by column chromatography to obtain the target compound Ⅰ-1.

[0089] 1 H NMR (400MHz, DMSO-d6): δ8.39(d,J=14.4Hz,1H),8.10(d,J=13.7Hz,1H),7.65–7.51(m,3H), 7.50–7.40(m,2H),7.34(dd,J=7.9,3.7Hz,3H),7.30–7.10(m,5H),6.24(dd,J=22.2,14.2Hz ,2H),5.59(s,2H),4.44(s,4H),2.77–2.59(m,9H),2.56(d,J=7.0Hz,2H),2.24(t,J=7.4Hz, 2H), 1.96 (p, J = 7.2Hz, 2H), 1.86–1.79 (m, 2H), 1.71 (q, J = 7.2Hz, 3H), 1.63 (d, J = 2.9Hz, 12H).

[0090] The UV absorption spectra and fluorescence emission spectra of compound Ⅰ-1 in water and ethanol are shown as follows: Figure 2 and Figure 3 As shown, the absorption and emission spectra of compound Ⅰ-1 in the two solvents are significantly different, among which the absorption spectrum of Ⅰ-1 in aqueous solution is wider and the emission light is less, approaching zero, indicating that the physical properties of compound Ⅰ-1 in aqueous solution and organic solvent are different.

[0091] Example 2 Synthesis of Compounds Ⅰ-2 to Ⅰ-13

[0092] Compounds Ⅰ-2 to Ⅰ-13 can be prepared by a method similar to Example 1.

[0093] 1. Synthesis of Compound Ⅰ-2

[0094]

[0095] Compound 12 in Example 1 was replaced by compound 13, and the remaining reagents and preparation methods were the same as steps 1 to 8 of Example 1 to prepare compound Ⅰ-2.

[0096] 1H NMR (400MHz, DMSO-d6): δ7.65–7.58(m,2H),7.40–7.20(m,7H),7.20–7.13(m,2H),7. 05–6.99(m,3H),6.96(d,J=8.1Hz,1H),6.83(dd,J=6.6,1.5Hz,1H),6.33(dt,J=8.1,0 .9Hz,1H),5.55(t,J=1.0Hz,2H),4.33(t,J=5.8Hz,2H),4.11(t,J=5.8Hz,2H),2.73(d t,J=6.9,5.8Hz,4H),2.67–2.53(m,6H),1.99–1.86(m,4H),1.58(s,8H),1.54(s,6H).

[0097] 2. Synthesis of Compound Ⅰ-3

[0098]

[0099] Compounds 14 and 15 were used to replace compounds 10 and 12 in Example 1. The remaining reagents and preparation methods were the same as steps 1 to 8 of Example 1 to prepare compound I-3.

[0100] 1 H NMR (400MHz, DMSO-d6): δ7.44–7.36(m,2H),7.34–7.28(m,2H),7.28–7.20(m,4H),7.20–7.14(m, 3H),7.14–7.08(m,2H),7.01(td,J=7.7,1.4Hz,1H),6.96(d,J=8.1Hz,1H),6.83(dd,J=6.6,1.5Hz ,1H),6.33(dt,J=8.1,0.9Hz,1H),4.33(t,J=5.8Hz,2H),4.28(t,J=1.0Hz,2H),4.11(t,J=5.8Hz ,2H),2.73(dt,J=6.9,5.8Hz,4H),2.67–2.53(m,6H),1.99–1.86(m,4H),1.56(d,J=21.4Hz,14H).

[0101] 3. Synthesis of Compound Ⅰ-4

[0102]

[0103] Compounds 14 and 16 were used to replace compounds 10 and 12 in Example 1 respectively, and the remaining reagents and preparation methods were the same as steps 1 to 8 of Example 1 to prepare compound I-4.

[0104] 1 H NMR (400MHz, DMSO-d6): δ7.61–7.55(m,2H),7.40–7.33(m,2H),7.33–7.27(m,3H),7.27–7.20(m ,2H),7.20–7.14(m,2H),7.14–7.08(m,2H),7.01(td,J=7.6,1.4Hz,1H),6.96(d,J=8.1Hz,1H), 6.83(dd,J=6.6,1.5Hz,1H),6.33(dt,J=8.1,0.9Hz,1H),4.40–4.30(m,4H),4.11(t,J=5.8Hz,2 H),2.73(dt,J=6.9,5.8Hz,4H),2.67–2.53(m,6H),1.99–1.86(m,4H),1.56(d,J=21.4Hz,14H).

[0105] 4. Synthesis of Compound Ⅰ-5

[0106]

[0107] Compound 14 was used to replace compound 10 in Example 1, and the remaining reagents and preparation methods were the same as steps 1 to 8 of Example 1 to prepare compound Ⅰ-5.

[0108] 1 H NMR (400MHz, DMSO-d6): δ7.43–7.35(m,2H),7.34–7.28(m,2H),7.28–7.20(m,4H),7.20–7.0 8(m,5H),7.01(td,J=7.7,1.4Hz,1H),6.96(d,J=8.1Hz,1H),6.83(dd,J=6.6,1.5Hz,1H),6.3 3(dt,J=8.1,0.9Hz,1H),4.57(t,J=0.9Hz,2H),4.33(t,J=5.8Hz,2H),4.11(t,J=5.8Hz,2H) ,2.73(dt,J=6.9,5.8Hz,4H),2.67–2.53(m,6H),1.99–1.86(m,4H),1.56(d,J=21.4Hz,14H).

[0109] 5. Synthesis of Compound Ⅰ-6

[0110]

[0111] Compounds 14 and 13 were used to replace compounds 10 and 12 in Example 1. The remaining reagents and preparation methods were the same as steps 1 to 8 of Example 1 to prepare compound I-6.

[0112] 1 H NMR (400MHz, DMSO-d6): δ7.70–7.64(m,2H),7.40–7.33(m,2H),7.33–7.08(m,9H),7.05–6.98( m,2H),6.83(dd,J=6.5,1.4Hz,1H),6.37(dt,J=8.1,1.0Hz,1H),4.59(dt,J=13.7,0.9Hz,1H), 4.55–4.49(m,1H),4.36(t,J=5.8Hz,2H),4.09(t,J=5.8Hz,2H),2.74(td,J=5.8,4.7Hz,4H),2 .67–2.56(m,6H),2.48(t,J=8.0Hz,2H),1.94(m,J=16.1,8.0,5.8Hz,4H),1.64–1.54(m,14H).

[0113] 6. Synthesis of Compound Ⅰ-7

[0114]

[0115] Compound 17 is used to replace compound 8 in Example 1, K can be selected from S, Se, Te, and the other required reagents and preparation methods are the same as steps 1 to 8 of Example 1 to prepare compound I-7.

[0116] 1 H NMR (400MHz, DMSO-d6): δ7.43–7.36(m,2H),7.34(dt,J=8.6,1.0Hz,2H),7.27–7.22(m,2H),7.21( dd,J=2.3,1.5Hz,3H),7.16(m,J=8.8,7.2,1.6Hz,2H),7.05–6.97(m,4H),6.83(dd,J=6.5,1.4Hz,1 H),6.37(dt,J=8.1,1.0Hz,1H),5.48(t,J=1.0Hz,2H),4.36(t,J=5.8Hz,2H),4.09(t,J=5.8Hz,2H ),2.72–2.52(m,10H),2.45(t,J=8.3Hz,2H),1.90(m,J=11.2,8.3,6.6Hz,4H),1.64–1.54(m,14H).

[0117] 7. Synthesis of Compound Ⅰ-8

[0118]

[0119] Compound 18 was used to replace compound 8 in Example 1, and the remaining reagents and preparation methods were the same as steps 1 to 8 of Example 1 to prepare compound I-8.

[0120] 1 H NMR (400MHz, DMSO-d6): δ7.44–7.36(m,2H),7.36–7.30(m,2H),7.27–7.22(m,2H),7.21(dd,J=2.3,1.5 Hz,3H),7.16(m,J=8.8,7.2,1.6Hz,2H),7.05–6.97(m,4H),6.83(dd,J=6.5,1.4Hz,1H),6.37(dt,J=8. 1,1.0Hz,1H),5.48(t,J=1.0Hz,2H),4.36(t,J=5.8Hz,2H),4.09(t,J=5.8Hz,2H),2.70(td,J=6.0,1.2 Hz,4H),2.67–2.54(m,6H),2.44(t,J=7.8Hz,2H),1.91(m,J=27.5,7.8,6.0Hz,4H),1.64–1.53(m,14H).

[0121] 8. Synthesis of Compound Ⅰ-9

[0122]

[0123] Compound 19 was used to replace compound 8 in Example 1, and the remaining reagents and preparation methods were the same as steps 1 to 8 of Example 1 to prepare compound I-9.

[0124] 1H NMR (4000MHz, DMSO-d6): δ7.44–7.37(m,2H),7.37–7.30(m,2H),7.27–7.22(m,2H),7.21(dd,J=2.3,1. 5Hz, 3H), 7.16 (m, J=8.8, 7.2, 1.6Hz, 2H), 7.05–6.97 (m, 4H), 6.83 (dd, J=6.5, 1.4Hz, 1H), 6.37 (dt, J=8. 1,1.0Hz,1H),5.48(t,J=1.0Hz,2H),4.36(t,J=5.8Hz,2H),4.09(t,J=5.8Hz,2H),2.77(td,J=5.4,1.7 Hz,4H),2.72–2.56(m,6H),2.48(t,J=8.1Hz,2H),1.97(m,J=25.2,8.1,5.3Hz,4H),1.64–1.54(m,14H).

[0125] 9. Synthesis of Compound Ⅰ-10

[0126]

[0127] Compound 20 was used to replace compound 8 in Example 1, and the remaining reagents and preparation methods were the same as steps 1 to 8 of Example 1 to prepare compound Ⅰ-10.

[0128] 1 H NMR (400MHz, DMSO-d6): δ7.44–7.37(m,2H),7.37–7.30(m,2H),7.27–7.13(m,7H),7.0 5–6.97(m,4H),6.83(dd,J=6.5,1.4Hz,1H),6.37(dt,J=8.1,1.0Hz,1H),5.48(t,J=1. 0Hz,2H),4.36(t,J=5.8Hz,2H),4.09(t,J=5.8Hz,2H),2.82(q,J=5.4Hz,4H),2.72–2. 56(m,6H),2.48(t,J=8.0Hz,2H),1.97(m,J=25.4,8.0,5.3Hz,4H),1.64–1.54(m,14H).

[0129] 10. Synthesis of Compound Ⅰ-11

[0130]

[0131] Compound 21 was used to replace compound 8 in Example 1, and the remaining reagents and preparation methods were the same as steps 1 to 8 of Example 1 to prepare compound Ⅰ-11.

[0132] 1 H NMR (400MHz, DMSO-d6): δ7.79(t,J=5.2Hz,2H),7.43–7.37(m,2H),7.37–7.30(m,2H),7.28–7.19(m,4H),7.19–7 .13(m,3H),7.05–6.99(m,3H),6.96(d,J=8.1Hz,1H),6.83(dd,J=6.6,1.5Hz,1H),6.33(dt,J=8.1,0.9Hz,1H),5. 47(t,J=1.0Hz,2H),4.33(t,J=5.8Hz,2H),4.11(t,J=5.8Hz,2H),3.30(m,J=5.9,1.3Hz,4H),2.63–2.57(m,3H),2 .57–2.54(m,1H),2.35(t,J=8.3Hz,2H),2.04(s,6H),1.86(m,J=14.4,8.4,5.9Hz,4H),1.58(s,8H),1.54(s,6H).

[0133] 11. Synthesis of Compound Ⅰ-12

[0134]

[0135] Compound 22 was used to replace compound 8 in Example 1, and the remaining reagents and preparation methods were the same as steps 1 to 8 of Example 1 to prepare compound I-12.

[0136] 1 H NMR (400MHz, DMSO-d6): δ7.62–7.56(m,4H),7.44–7.36(m,2H),7.36–7.30(m,2H),7. 27–7.13(m,11H),7.05–6.97(m,4H),6.83(dd,J=6.5,1.4Hz,1H),6.37(dt,J=8.1,1. 0Hz,1H),5.48(t,J=1.0Hz,2H),4.36(t,J=5.8Hz,2H),4.09(t,J=5.8Hz,2H),2.72–2 .53(m,10H),2.49(t,J=8.6Hz,2H),1.88(m,J=29.7,8.4Hz,4H),1.64–1.54(m,14H).

[0137] 12. Synthesis of Compound Ⅰ-13

[0138]

[0139] Compound 23 was used to replace compound 8 in Example 1, and the remaining reagents and preparation methods were the same as steps 1 to 8 of Example 1 to prepare compound I-13.

[0140] 1 H NMR (400MHz, DMSO-d6): δ7.42–7.38(m,2H),7.36–7.32(m,2H),7.26–7.14(m,7H),7.04 –6.96(m,4H),6.83(dd,J=6.5,1.4Hz,1H),6.39–6.34(m,1H),5.48(t,J=1.0Hz,2H),4.3 6(t,J=5.8Hz,2H),4.09(t,J=5.8Hz,2H),3.65(d,J=6.9Hz,4H),2.71–2.57(m,4H),2.54 –2.48(m,2H),2.40(t,J=8.2Hz,2H),1.71–1.62(m,7H),1.62–1.56(m,9H),1.55(s,6H).

[0141] Example 3 Preparation method of micro-nanostructure

[0142] Taking the micro-nanostructure self-assembled by compound Ⅰ-1 as an example, Ⅰ-1 is dissolved in DMSO (or an organic solvent such as ethanol) to prepare a 2mM storage solution, and 10μL of the storage solution is added to 2mL of deionized water to prepare nanoparticles.

[0143] Example 4 Characterization Method of Micro-Nano Structure

[0144] like Figure 4 As shown, 10 μL of the working solution of compound I-1 was added to the silicon wafer, and the micro-nanostructure in the form of nano-microspheres was observed and photographed under a transmission electron microscope (TEM). From the observation results, it was found that the particle size of the micro-nanostructure self-assembled by compound I-1 was about 160nm. At the same time, DLS was used to test the particle size of the nano-microspheres self-assembled by compound I-1 in aqueous solution. The results were as follows: Figure 5 As shown, the particle size is around 30nm to 200nm, and there is no obvious change in the particle size after being placed at room temperature for 24 hours, which proves that the compound has excellent structural stability.

[0145] Test Example 1 In vitro photothermal effect of compound Ⅰ-1

[0146] Take 3 mL of each of the 4 groups of samples and add them to the cuvette, then seal it with a lid.

[0147] Sample No. 1 was 3 mL of deionized water;

[0148] Sample No. 2 is 10 μM Ⅰ-1, and the specific preparation method is 3 mL of deionized water plus 15 μL of Ⅰ-1 stock solution (2 mM, dissolved in DMSO);

[0149] Sample No. 3 is 20 μM Ⅰ-1, and the specific preparation method is 3 mL of deionized water plus 30 μL of Ⅰ-1 stock solution (2 mM, dissolved in DMSO);

[0150] Sample No. 4 is 40 μM Ⅰ-1, and the specific preparation method is 3 mL of deionized water plus 60 μL of Ⅰ-1 stock solution (2 mM, dissolved in DMSO).

[0151] Each sample was irradiated with 808 nm laser for 10 minutes, and the temperature data was recorded every 10 seconds using a thermal imager. The temperature corresponding to the time was plotted. Figure 7 The temperature of sample No. 1 remained almost unchanged within 10 minutes, rising only 2.4°C; the temperature of sample No. 2 rose from 21.6°C at room temperature to 40.4°C, an increase of 18.8°C; the temperature of sample No. 3 rose from 23°C at room temperature to 53.6°C, an increase of 30.6°C; the temperature of sample No. 4 rose from 23°C at room temperature to 67.3°C, an increase of 44.3°C.

[0152] Sample No. 2 was selected to test the light and heat stability experiment. Figure 6 As shown, after irradiation with 808nm laser for 10 minutes, sample No. 2 rose from room temperature 21.6℃ to 40.4℃. After cooling naturally for fifteen minutes, it was irradiated with 808nm laser again for 10 minutes, and then cooled naturally, and repeated 5 times. After 5 repeated irradiations, sample 2 can still be heated from 21.6℃ to 28.7℃, proving that it can still release a stable photothermal effect during repeated heating and cooling, and has good photothermal stability. At the same time, we calculated the photothermal conversion efficiency of compound I-1 and found that its photothermal conversion efficiency is as high as 46.06%, indicating that compound I-1 has excellent photothermal effect. The photothermal conversion efficiency of Cy7-TCF-OH decomposed after I-1 is stimulated is as high as 59.21%, which lays a theoretical foundation for gas therapy combined with phototherapy.

[0153] Test Example 2 In vitro photodynamic effect of compound Ⅰ-1

[0154] First, 2 ml of 10 μM aqueous solution of compound Ⅰ-1 was prepared, and ultrapure water and Cy7-TCF-OH groups were used as controls. The reactive oxygen indicating probe 1,3-diphenylisobenzofuran (DPBF) was added to the samples to a final concentration of 50 μM, and the UV absorption after adding DPBF was measured using a UV-visible spectrophotometer, which was recorded as the initial absorbance. An 808 nm laser was used at 1 W / cm 2The sample was irradiated with a laser intensity of 100 nm and the absorbance was measured every 30 seconds for a total of 5 minutes. The absorbance results at 420 nm in the DPBF UV absorption data were read and compared with the initial absorbance A0. Figure 8 As shown, under the same excitation light irradiation conditions, as the irradiation time increases, the DPBF absorption value of the blank group shows a certain degree of decrease, compound Ⅰ-1 shows a slight decrease in absorbance, and Cy7-TCF-OH shows a significant decrease in absorbance. This result shows that the Cy7-TCF-OH molecules produced by compound Ⅰ-1 after stimulation have a strong ability to release singlet oxygen under 808nm near-infrared light irradiation. At the same time, since compound Ⅰ-1 can form nanoparticles through self-assembly in aqueous solution, the photostability and in vivo circulation stability are increased, and it has the potential to be used as a photosensitizer for PDT in tumors.

[0155] Experimental Example 3 Cell Imaging Experiment

[0156] The nuclear dye Hoechst33342 (100nM) and I-1 (10μM) were added to the cell culture medium with the lysosomal dye Lyso-Green (75nM) or the mitochondrial dye Mito-Green (75nM) for 30 minutes of cell staining. After staining, the cells were rinsed twice with PBS solution and then observed and photographed under a confocal fluorescence microscope. Fig. 9 As shown, it indicates that compound I-1 is successfully taken up by cells and distributed in lysosomes and mitochondria, and the Pearson correlation coefficient of its distribution in mitochondria is 0.79.

[0157] Experimental Example 4 Intracellular Reactive Oxygen Generation Detection Experiment

[0158] HeLa cells were plated at 10 5 The cells were initially cultured in a 24-well plate. After 24 hours, Ⅰ-1 was added at a concentration of 10 μM, and a blank control (no sample was added, only DCFH-DA was added) and a Cy7-TCF-OH group were set as controls. After 2 hours of co-incubation, the cells were washed twice with PBS, and serum-free culture medium containing DCFH-DA (5 μM) was added to each well and incubated for 30 minutes. After washing with PBS, the sample group was divided into a group with or without laser irradiation. The irradiation group used an 808 nm laser to select 0.5 W / cm 2 The laser intensity was set at 100 nm and each well was irradiated for 6 min. Then the production of reactive oxygen species in the cells was investigated using a laser confocal microscope. Fig.10As shown. It can be seen that due to the high level of reactive oxygen species in tumor cells, green fluorescence of lower intensity can be observed by adding only the DCFH-DA probe group. Regardless of whether it is illuminated or not, the green fluorescence intensity of group Ⅰ-1 is almost the same as that of the blank group, while obvious green fluorescence is observed over a large range in the Cy7-TCF-OH group with laser irradiation. Combined with the results of in vitro photodynamic therapy, compound I-1 itself has no obvious photodynamic therapy effect, but the Cy7-TCF-OH generated after being stimulated by the tumor microenvironment has a strong ability to produce reactive oxygen species. This result shows that after being stimulated by the tumor cell microenvironment, Ⅰ-1 can produce reactive oxygen species under near-infrared light irradiation, which makes it possible for Ⅰ-1 nanoparticles to perform photodynamic therapy.

[0159] Experimental Example 5 Intracellular Therapeutic Effect Detection Experiment

[0160] HeLa cells were plated at 10 4 The cells were initially cultured in a 96-well plate. After 24 hours, different concentrations (0.1 μM to 100 μM) of Ⅰ-1 were added. After the dark toxicity test, the wells were placed in an incubator for 24 hours and then observed under a fluorescence microscope. It was found that almost all the cells survived. Fig.11 As shown, it is proved that compound Ⅰ-1 itself has very low toxicity.

[0161] like Fig.12 As shown, the cell wells tested for phototoxicity were exposed to 0.5 W / cm 2 Each well was irradiated for 6 minutes under 808nm laser, and stained with live cell dye Calcein-AM and dead cell dye EthD-I for 20 minutes. Then photos were taken under a fluorescence microscope and it was found that 95.5% of the cells died when the concentration of Ⅰ-1 was greater than 12.5μM, proving that compound Ⅰ-1 has a strong killing effect on cancer cells under laser irradiation and has excellent phototherapy / gas combined treatment effect.

[0162] Comparison of the results of the phototoxicity group and the dark toxicity group shows that the compound itself has very low toxicity and exhibits excellent optical killing effect on cancer cells, and has great potential in the clinical application of light therapy for cancer. Other compounds of the present invention also have similar light therapy effects.

[0163] Experimental Example 6: In vivo fluorescence imaging experiment in mice

[0164] First, a mouse tumor model was constructed. Female nude mice aged 4 to 5 weeks were selected and 4×10 6 Mouse breast cancer cells 4T1 in logarithmic growth phase were injected subcutaneously in the chest of mice. When the tumor volume grew to 80 mm 3The drug was administered by tail vein injection according to the weight of the mice, and the fluorescence intensity of the chest tumor was continuously monitored by in vivo fluorescence imaging for 120 hours. Fig.14 As shown. The continuous imaging monitoring results of the fluorescence intensity at the chest tumor of group Ⅰ-1 showed that after injection through the tail vein, Ⅰ-1 nanoparticles can accurately target the tumor location through the EPR effect and accumulate at the tumor, but the fluorescence signal is weak due to fluorescence quenching caused by aggregation. As the high level of GSH in the tumor microenvironment continues to stimulate the disulfide bonds of Ⅰ-1, the fluorescence quenching caused by aggregation of Ⅰ-1 nanoparticles is restored after responding to GSH, and the binding of the generated Cy7-TCF-OH to serum proteins is enhanced, so the fluorescence at the tumor continues to increase, achieving high-resolution enhanced fluorescence imaging at the tumor tissue. At the same time, the fluorescence intensity results at the tumor after 120 hours show that it also shows stable and long-term accumulation and fluorescence emission in the tumor tissue, and has the applicability in the early detection, contour measurement and fluorescence imaging-guided surgical resection of tumor tissue in vivo, and has the potential to be used as an integrated diagnosis and treatment reagent.

[0165] Experimental Example 7 Photoacoustic imaging test of mouse tumors

[0166] First, a mouse tumor model was constructed. 4×10 6 4T1 cells, when the tumor volume grows to 75mm 3 200 μg of compound II-1 was injected into mice via tail vein injection. The three-dimensional photoacoustic tomography system was used to monitor at different time points. Fig.15 As shown, after injection, the fluorescence of the mouse tumor site gradually increased over time within 1-12 hours, and there was still a strong photoacoustic signal at 24 hours. This example proves that compound II-1 has excellent photoacoustic signals. Moreover, within 24 hours, the nude mice did not experience spasms, convulsions, and other abnormalities, proving that compound II-1 has low toxicity and high safety

[0167] Experimental Example 8: Optical therapy experiment in mice

[0168] The nude mice were divided into 7 groups. Group 1 was injected with saline without laser irradiation; Group 2 was injected with saline and laser irradiated for 10 minutes; Group 3 was injected with 200 μL Ⅰ-1 (200 μg) without laser irradiation; Group 4 was injected with 200 μL Cy7-TCF-OH (200 μg) through the tail vein of the mice and laser irradiated with 0.5 W / cm 2 The tumor sites of mice were irradiated with 808 nm laser for 10 min. Group 5 was injected with 200 μL Cy7-TCF-OH (200 μg) and laser was used at 0.25 W / cm 2The 808 nm laser was used to irradiate the tumor site of mice for 10 minutes; in group 6, 200 μL of I-1 (200 μg) was injected into the mice through the tail vein and 0.5 W / cm 2 The 808 nm laser was used to irradiate the tumor site of mice for 10 minutes; in group 6, 200 μL I-1 (200 μg) was injected into the mice through the tail vein and 0.25 W / cm 2 The 808nm laser was used to irradiate the tumor site of the mouse for 10 minutes. During the laser irradiation, the tumor site was continuously photographed using a photothermal imager. The imaging results are shown in Fig.16 After the treatment, in order to accurately monitor the changes in the mouse tumor, the tumor site of the mouse was photographed and recorded every day, and the tumor volume and weight changes of each group of mice were measured, and the records were continuously recorded for 15 days.

[0169] like Fig.17 As shown, Ⅰ-1 and Cy7-TCF-OH group 0.5W / cm 2 The mice treated with laser irradiation had ulceration at the tumor site the next day due to the increase in local temperature and the increase in the concentration of reactive oxygen under light. As time went on, no obvious tumor growth was observed at the primary tumor site of the mice in both groups, and the ulceration site began to heal. On the 15th day, the ulceration site had completely healed, leaving only a tiny scar. 0.25W / cm 2 The Cy7-TCF-OH group showed relapse on the 4th day, while the 0.25W / cm 2 The Ⅰ-1 group relapsed on the 8th day, and the tumor volume on the 15th day was much smaller than that of the Cy7-TCF-OH group. This shows that I-1 has excellent hypothermic therapeutic effects. There was no abnormal change in the body weight of mice in the experimental and control groups after phototherapy, and no obvious side effects of Ⅰ-1 were observed, which was safe and reliable. This result proves that Ⅰ-1 nanoparticles can stably passively target and accumulate at the tumor site through the blood circulation, and show excellent phototherapy / gas synergistic therapeutic ability under near-infrared light irradiation, and the treatment has few side effects and is safe and reliable. Combined with the fluorescence imaging effect shown, it is proved that Ⅰ-1 has the potential to prepare highly safe integrated diagnosis and treatment reagents.

[0170] Test Example 9 Safety test of compound Ⅰ-1 in mice

[0171] The nude mice were divided into 6 groups. The first group was injected with normal saline through the tail vein, and the other 5 groups were injected with Ⅰ-1. The blood of the 6 groups of injected female Kunming mice was taken for blood routine and liver function tests. Fig. 20As shown, the blood routine indicators such as lymphocytes, mean corpuscular volume and red blood cell volume distribution width of the six groups of mice were all within the normal range, and the liver function indicators such as blood protein, alkaline phosphatase and blood sugar were all within the normal range. The results show that compound Ⅰ-1 has a high safety profile, does not damage the liver in the short term, and is relatively safe and reliable. At the same time, after the end of in vivo phototherapy, the main organs of the mice, including the heart, liver, spleen, lungs, and kidneys, were dissected out and fixed with formalin and then sectioned. The samples were stained with hematoxylin-eosin (H&E) and pathological histological analysis was performed to evaluate whether the drugs caused damage to the organs after phototherapy. The staining results are shown in the figure below. Fig.21 As shown, compared with the normal saline group, the Ⅰ-1 injection group did not cause obvious damage to major tissues and organs, showing good biosafety.

[0172] The above description is only a preferred embodiment of the present invention, and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art can still modify the technical solutions described in the above embodiments, or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, modification, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A diagnostic and therapeutic integrated compound with stimulus responsiveness, characterized in that: The compound has a structure represented by formula (I) or a micro-nano structure formed by self-assembly of its isomers, pharmaceutically acceptable salts, hydrates or solvates in aqueous solution: In the above formula (I): B is a stimulus response group, including In the formula (I), X, Y and Z are independently selected from O or S.

2. The compound according to claim 1, characterized in that The compound is compound Ⅰ-1, Ⅰ-2, Ⅰ-3, Ⅰ-4, Ⅰ-5, Ⅰ-6, Ⅰ-7, Ⅰ-8, Ⅰ-9, Ⅰ-10, Ⅰ-11, Ⅰ-12 or Ⅰ-13.

3. The compound according to any one of claims 1 to 2, characterized in that The micro-nano structure of the compound is a nano-microsphere structure formed by self-assembly of the compound having the structure shown in formula (I), its isomer, pharmaceutically acceptable salt, hydrate or solvate in aqueous solution.

4. A pharmaceutical composition, characterized in that The invention comprises the compound according to any one of claims 1 to 3, and a pharmaceutically acceptable carrier.

5. Use of the compound according to any one of claims 1 to 3 and the pharmaceutical composition according to claim 4 in the preparation of fluorescent probes, preparation of H2S donors and phototherapy drugs, preparation of drugs for diagnosing and / or treating cancer, phototherapy combined with gas therapy, and stimulus-responsive release of drugs.

6. The use according to claim 5, characterized in that: The cancer includes esophageal cancer, non-small cell lung cancer, biliary tract cancer, head and neck cancer, Barrett's esophagitis, bladder cancer, colorectal cancer, pancreatic cancer, ovarian cancer, prostate cancer, brain tumor, breast cancer or skin cancer; the tissue inflammation includes myocarditis, tracheitis, bronchitis, pharyngitis, tonsillitis, enteritis, gastritis, duodenitis; the phototherapy drug is a photodynamic therapy drug, a photothermal therapy drug or a photoacoustic therapy drug; the H2S donor is a COS / H2S donor; the stimulus responsive release includes reactive oxygen response, reduction response, enzyme response, pH response, hypoxia response, temperature response, light response, acoustic response and magnetic response.

Citation Information

Patent Citations

  • Supramolecular photothermal agent compound with stimuli responsiveness and composition and application of supramolecular photothermal agent compound

    CN113321644A

  • Hydrogen sulfide donor, preparation method and application thereof

    CN113480458A

  • Stimuli-responsive nano-drug for low-temperature photo-thermal therapy

    CN116120298A

  • Compound for photothermal-immune combined treatment of tumors and application thereof

    CN116462681A

  • Polymerizable cyanine dye based on disulfide bond as well as synthesis method and application of polymerizable cyanine dye

    CN118271304A

Cited By

  • Para-substituted heptamethine quinone cyanine dye as well as synthesis method and application thereof

    CN119707859A

  • Para-substituted heptamethine cyanine dyes and methods of synthesis and use thereof

    CN119707859B